



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 



# Aspartoacylase (m): 293T Lysate: sc-125004

## BACKGROUND

Aspartoacylase, also known as ASPA, ACY2 or ASP, is a 313 amino acid protein that is expressed in liver, lung and kidney tissue, as well as in skeletal muscle and in cerebral white matter. Existing as a homodimer, Aspartoacylase functions to catalyze the deacetylation of N-acetylaspatic acid (NAA) (a protein whose hydrolysis is crucial to maintenance of intact white matter) to produce acetate and L-aspartate. Defects in the gene encoding Aspartoacylase are the cause of Canavan disease (CAND), which is a rare neurodegenerative condition that is characterized by white matter vacuolization and demyelination, resulting in a spongy deterioration of brain tissue. CAND is generally characterized by atonia of neck muscles, hypotonia, hyperextension of legs and flexion of arms, blindness, severe mental retardation, megaloccephaly and death.

## REFERENCES

1. Kaul, R., et al. 1993. Cloning of the human Aspartoacylase cDNA and a common missense mutation in Canavan disease. *Nat. Genet.* 5: 118-123.
2. Kaul, R., et al. 1994. Canavan disease: mutations among Jewish and non-Jewish patients. *Am. J. Hum. Genet.* 55: 34-41.
3. Olsen, T.R., et al. 2002. Two novel Aspartoacylase gene (ASPA) missense mutations specific to Norwegian and Swedish patients with Canavan disease. *J. Med. Genet.* 39: e55.
4. Online Mendelian Inheritance in Man, OMIM™. 2002. Johns Hopkins University, Baltimore, MD. MIM Number: 608034. World Wide Web URL: <http://www.ncbi.nlm.nih.gov/omim/>
5. Le Coq, J., et al. 2006. Characterization of human Aspartoacylase: the brain enzyme responsible for Canavan disease. *Biochemistry* 45: 5878-5884.
6. Hershfield, J.R., et al. 2006. Aspartoacylase is a regulated nuclear-cytoplasmic enzyme. *FASEB J.* 20: 2139-2141.
7. Hershfield, J.R., et al. 2007. Mutational analysis of Aspartoacylase: implications for Canavan disease. *Brain Res.* 1148: 1-14.
8. Bitto, E., et al. 2007. Structure of Aspartoacylase, the brain enzyme impaired in Canavan disease. *Proc. Natl. Acad. Sci. USA* 104: 456-461.
9. Le Coq, J., et al. 2008. Examination of the mechanism of human brain Aspartoacylase through the binding of an intermediate analogue. *Biochemistry* 47: 3484-3492.

## CHROMOSOMAL LOCATION

Genetic locus: *Acy3* (mouse) mapping to 19 A.

## PRODUCT

Aspartoacylase (m): 293T Lysate represents a lysate of mouse Aspartoacylase transfected 293T cells and is provided as 100 µg protein in 200 µl SDS-PAGE buffer.

## STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

## APPLICATIONS

Aspartoacylase (m): 293T Lysate is suitable as a Western Blotting positive control for mouse reactive Aspartoacylase antibodies. Recommended use: 10-20 µl per lane.

Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

## RESEARCH USE

For research use only, not for use in diagnostic procedures.

## PROTOCOLS

See our web site at [www.scbt.com](http://www.scbt.com) for detailed protocols and support products.